772 related articles for article (PubMed ID: 33716004)
1. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
Ciardullo S; Perseghin G
Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
Zhang X; Heredia NI; Balakrishnan M; Thrift AP
PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
[TBL] [Abstract][Full Text] [Related]
3. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
Ciardullo S; Monti T; Perseghin G
Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.
Ciardullo S; Cannistraci R; Mazzetti S; Mortara A; Perseghin G
Front Endocrinol (Lausanne); 2021; 12():711484. PubMed ID: 34381424
[TBL] [Abstract][Full Text] [Related]
5. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
11. Lack of awareness of liver organ damage in patients with type 2 diabetes.
Ciardullo S; Monti T; Perseghin G
Acta Diabetol; 2021 May; 58(5):651-655. PubMed ID: 33496855
[TBL] [Abstract][Full Text] [Related]
12. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
Kwok R; Choi KC; Wong GL; Zhang Y; Chan HL; Luk AO; Shu SS; Chan AW; Yeung MW; Chan JC; Kong AP; Wong VW
Gut; 2016 Aug; 65(8):1359-68. PubMed ID: 25873639
[TBL] [Abstract][Full Text] [Related]
13. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population.
Ciardullo S; Ballabeni C; Trevisan R; Perseghin G
Dig Liver Dis; 2021 Jul; 53(7):866-872. PubMed ID: 33685807
[TBL] [Abstract][Full Text] [Related]
14. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population.
Ciardullo S; Muraca E; Zerbini F; Manzoni G; Perseghin G
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2856-e2865. PubMed ID: 33878156
[TBL] [Abstract][Full Text] [Related]
15. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
[TBL] [Abstract][Full Text] [Related]
16. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
Kong AP; Lau ES; O CK; Luk AO; Yip TC; Chow EY; Kwok R; Lee HW; Wong GL; Ma RC; Chan HL; Wong VW; Chan JC
Diabetes Res Clin Pract; 2023 Aug; 202():110825. PubMed ID: 37442241
[TBL] [Abstract][Full Text] [Related]
17. Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes.
Grgurevic I; Salkic N; Mustapic S; Bokun T; Podrug K; Marusic S; Rahelic D; Matic T; Skurla V; Mikolasevic I
Can J Gastroenterol Hepatol; 2021; 2021():5582813. PubMed ID: 33763391
[TBL] [Abstract][Full Text] [Related]
18. Association between hypertension and the prevalence of liver steatosis and fibrosis.
Fu H; Yu H; Zhao Y; Chen J; Liu Z
BMC Endocr Disord; 2023 Apr; 23(1):85. PubMed ID: 37081417
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population.
Ciardullo S; Monti T; Grassi G; Mancia G; Perseghin G
J Hypertens; 2021 Aug; 39(8):1621-1627. PubMed ID: 33657584
[TBL] [Abstract][Full Text] [Related]
20. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
